UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2323) 2323
science & technology (2157) 2157
life sciences & biomedicine (2074) 2074
female (1231) 1231
male (1187) 1187
oncology (1150) 1150
quinazolines - pharmacokinetics (948) 948
quinazolines - therapeutic use (903) 903
quinazolines - pharmacology (901) 901
animals (900) 900
quinazolines - administration & dosage (877) 877
middle aged (828) 828
pharmacology & pharmacy (796) 796
aged (750) 750
adult (726) 726
quinazolines - adverse effects (657) 657
mice (469) 469
lung neoplasms - drug therapy (462) 462
erlotinib hydrochloride (457) 457
antineoplastic agents - therapeutic use (456) 456
receptor, epidermal growth factor - antagonists & inhibitors (454) 454
treatment outcome (453) 453
carcinoma, non-small-cell lung - drug therapy (429) 429
cancer (414) 414
dose-response relationship, drug (385) 385
cell line, tumor (368) 368
gefitinib (359) 359
medicine & public health (356) 356
antineoplastic combined chemotherapy protocols - therapeutic use (354) 354
antineoplastic agents - pharmacology (341) 341
antineoplastic agents - pharmacokinetics (333) 333
care and treatment (328) 328
erlotinib (302) 302
research (301) 301
protein kinase inhibitors - therapeutic use (295) 295
neoplasms - drug therapy (275) 275
quinazolines - chemistry (272) 272
rats (271) 271
antineoplastic agents - adverse effects (266) 266
protein kinase inhibitors - pharmacology (265) 265
pharmacokinetics (263) 263
analysis (262) 262
chemotherapy (259) 259
drug therapy (257) 257
epidermal growth factor (256) 256
aged, 80 and over (253) 253
pharmacology/toxicology (250) 250
administration, oral (244) 244
antineoplastic agents - administration & dosage (219) 219
lung cancer, non-small cell (219) 219
mutation (215) 215
receptor, epidermal growth factor - metabolism (212) 212
quinazolines - blood (206) 206
breast cancer (204) 204
receptor, epidermal growth factor - genetics (204) 204
lung neoplasms - pathology (201) 201
tyrosine (201) 201
breast neoplasms - drug therapy (200) 200
protein kinase inhibitors - pharmacokinetics (196) 196
clinical trials (194) 194
lung cancer (192) 192
tumors (189) 189
antineoplastic combined chemotherapy protocols - adverse effects (182) 182
chemistry (182) 182
egfr (177) 177
lapatinib (177) 177
physical sciences (176) 176
drug administration schedule (173) 173
cancer research (172) 172
carcinoma, non-small-cell lung - pathology (171) 171
clinical trials as topic (168) 168
antineoplastic agents (167) 167
protein kinase inhibitors - adverse effects (162) 162
protein kinase inhibitors - administration & dosage (161) 161
kinases (159) 159
disease-free survival (156) 156
antimitotic agents (155) 155
area under curve (155) 155
cell proliferation - drug effects (152) 152
metastasis (152) 152
mice, nude (152) 152
drug interactions (149) 149
pharmacology (148) 148
biochemistry & molecular biology (146) 146
maximum tolerated dose (142) 142
xenograft model antitumor assays (140) 140
quinazolines - metabolism (139) 139
health aspects (138) 138
dosage and administration (137) 137
lung neoplasms - genetics (136) 136
structure-activity relationship (136) 136
hematology, oncology and palliative medicine (134) 134
epidermal growth factor receptor (133) 133
tissue distribution (132) 132
carcinoma, non-small-cell lung - genetics (129) 129
cancer therapies (127) 127
chemistry, medicinal (127) 127
drug resistance, neoplasm (127) 127
receptor, erbb-2 - antagonists & inhibitors (126) 126
antineoplastic combined chemotherapy protocols - pharmacokinetics (124) 124
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2696) 2696
Chinese (13) 13
Japanese (13) 13
French (9) 9
German (9) 9
Danish (2) 2
Hungarian (2) 2
Portuguese (2) 2
Spanish (2) 2
Bulgarian (1) 1
Italian (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2006, Volume 12, Issue 7, pp. 2166 - 2171
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 09/2013, Volume 31, Issue 27, pp. 3327 - 3334
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 03/2008, Volume 26, Issue 7, pp. 1119 - 1127
Journal Article
Therapeutic drug monitoring, ISSN 0163-4356, 2014, Volume 36, Issue 3, pp. 326 - 334
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 07/2017, Volume 35, Issue 19, pp. 2193 - 2202
...). Response rate and pharmacokinetic analysis were secondary end points. Results Between June 2015 and May 2016, 26 women were enrolled... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Piperazines - administration & dosage | Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors | Phthalazines - pharmacokinetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Genital Neoplasms, Female - drug therapy | Adult | Female | Quinazolines - administration & dosage | Piperazines - pharmacokinetics | Phthalazines - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Genital Neoplasms, Female - immunology | B7-H1 Antigen - immunology | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Genital Neoplasms, Female - metabolism | Protein Kinase Inhibitors - administration & dosage | B7-H1 Antigen - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | B7-H1 Antigen - biosynthesis | Quinazolines - adverse effects | Aged | Genital Neoplasms, Female - pathology | Phthalazines - adverse effects | Lymphocytes, Tumor-Infiltrating - immunology | Index Medicus | Phase I and Clinical Pharmacology | Combined Modality | Breast Cancer | ORIGINAL REPORTS
Journal Article
Cancer treatment reviews, ISSN 0305-7372, 2009, Volume 35, Issue 8, pp. 692 - 706
.... Post marketing study commitments have been made upon (accelerated) approval such as additional pharmacokinetic studies in patients with renal- or hepatic impairment... 
Hematology, Oncology and Palliative Medicine | Excretion | Absorption | Metabolism | Tyrosine kinase inhibitors | Distribution | Drug transporters and interactions | Life Sciences & Biomedicine | Oncology | Science & Technology | Erlotinib Hydrochloride | Niacinamide - analogs & derivatives | Pyrroles - pharmacokinetics | Humans | Cytochrome P-450 Enzyme System - metabolism | Pyridines - pharmacokinetics | Quinazolines - pharmacokinetics | Biological Availability | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Intestinal Absorption | Thiazoles - pharmacokinetics | Antineoplastic Agents - metabolism | Tissue Distribution | Benzenesulfonates - pharmacokinetics | Drug Interactions | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Piperazines - pharmacokinetics | Protein Kinase Inhibitors - pharmacokinetics | Dasatinib | Administration, Oral | Imatinib Mesylate | Protein Kinase Inhibitors - blood | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Agents - blood | Pyrimidines - pharmacokinetics | Indoles - pharmacokinetics | Protein Kinase Inhibitors - pharmacology | Benzamides | Protein Kinase Inhibitors - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Care and treatment | Oncology, Experimental | Cytochrome P-450 | Physiological aspects | Phenols | Research | Phosphotransferases | Protein binding | Cancer | Index Medicus
Journal Article